company background image

Leap Therapeutics NasdaqGM:LPTX Stock Report

Last Price


Market Cap







03 Oct, 2022


Company Financials +
LPTX fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

LPTX Stock Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.

Leap Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Leap Therapeutics
Historical stock prices
Current Share PriceUS$0.90
52 Week HighUS$3.77
52 Week LowUS$0.85
1 Month Change-39.74%
3 Month Change-25.17%
1 Year Change-74.92%
3 Year Change-24.55%
5 Year Change-83.62%
Change since IPO-88.58%

Recent News & Updates

Aug 12

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Leap Therapeutics press release (NASDAQ:LPTX): Q2 GAAP EPS of -$0.15 misses by $0.05. Cash and cash equivalents totaled $90.9 million at June 30, 2022, expected to provide financial runway to mid-2024 Shares +1.54% PM.

Shareholder Returns

LPTXUS BiotechsUS Market

Return vs Industry: LPTX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: LPTX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is LPTX's price volatile compared to industry and market?
LPTX volatility
LPTX Average Weekly Movement12.7%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: LPTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: LPTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

201136Doug Onsi

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd.

Leap Therapeutics Fundamentals Summary

How do Leap Therapeutics's earnings and revenue compare to its market cap?
LPTX fundamental statistics
Market CapUS$88.91m
Earnings (TTM)-US$49.33m
Revenue (TTM)US$750.00k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LPTX income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$750.00k
Other ExpensesUS$50.08m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.50
Gross Margin100.00%
Net Profit Margin-6,576.93%
Debt/Equity Ratio0%

How did LPTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is LPTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LPTX?

Other financial metrics that can be useful for relative valuation.

LPTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does LPTX's PB Ratio compare to its peers?

LPTX PB Ratio vs Peers
The above table shows the PB ratio for LPTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1x
ADVM Adverum Biotechnologies
FIXX Homology Medicines
CUE Cue Biopharma
MRZM Marizyme
LPTX Leap Therapeutics

Price-To-Book vs Peers: LPTX is expensive based on its Price-To-Book Ratio (1.1x) compared to the peer average (1x).

Price to Earnings Ratio vs Industry

How does LPTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: LPTX is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is LPTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LPTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LPTX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of LPTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LPTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LPTX's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Leap Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LPTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LPTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LPTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LPTX is forecast to have no revenue next year.

High Growth Revenue: LPTX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LPTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Leap Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LPTX is currently unprofitable.

Growing Profit Margin: LPTX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: LPTX is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.

Accelerating Growth: Unable to compare LPTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LPTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: LPTX has a negative Return on Equity (-59.2%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Leap Therapeutics's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LPTX's short term assets ($92.4M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: LPTX's short term assets ($92.4M) exceed its long term liabilities ($474.0K).

Debt to Equity History and Analysis

Debt Level: LPTX is debt free.

Reducing Debt: LPTX had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LPTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LPTX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 8.7% each year.

Discover healthy companies


What is Leap Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Leap Therapeutics Dividend Yield vs Market
How does Leap Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Leap Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Leap Therapeutics)n/a

Notable Dividend: Unable to evaluate LPTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LPTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LPTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LPTX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LPTX has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Doug Onsi (53 yo)





Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since 2020. He serves as Managing Director of HealthCare Ventures LLC. He joined the HealthCare Ventures LLC in...

CEO Compensation Analysis

Doug Onsi's Compensation vs Leap Therapeutics Earnings
How has Doug Onsi's remuneration changed compared to Leap Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$2mUS$596k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$2mUS$513k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$817kUS$400k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$682kUS$400k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$3mUS$397k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$381kUS$350k


Compensation vs Market: Doug's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: LPTX's management team is considered experienced (2.5 years average tenure).

Board Members

Experienced Board: LPTX's board of directors are considered experienced (5.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LPTX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies00%
Individual Insiders2,5800.003%
Public Companies9,168,1959.3%
VC/PE Firms14,714,65814.9%
General Public45,256,61245.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.

Top Shareholders

Top 25 shareholders own 52.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Perceptive Advisors LLC
BeiGene, Ltd.
7,348,437$6.6m0%no data
HealthCare Ventures LLC
Artal Group S.A.
Rock Springs Capital Management LP
The Vanguard Group, Inc.
3,256,331$2.9m0%no data
M28 Capital Management LP
Eli Lilly and Company
1,819,758$1.6m0%no data
683 Capital Management, LLC
Platinum Investment Management Limited
Tang Capital Management, LLC
BlackRock, Inc.
1,199,035$1.1m0.07%no data
Millennium Management LLC
1,175,530$1.1m-24.55%no data
HealthCor Management L.P.
Key Client Fiduciary Advisors, LLC
Marshall Wace LLP
811,435$728.6k-49.3%no data
Adage Capital Management, L.P.
800,000$718.3k0%no data
Two Sigma Advisers, LP
755,600$678.5k-29.24%no data
Renaissance Technologies LLC
620,820$557.4k0%no data
Geode Capital Management, LLC
608,765$546.6k0%no data
Baker Bros. Advisors LP
559,705$502.6k0%no data
DLD Asset Management, LP
Knott Partners Management, LLC
Bridgeway Capital Management, LLC
ACT Capital Management

Company Information

Leap Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Leap Therapeutics, Inc.
  • Ticker: LPTX
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$88.911m
  • Shares outstanding: 99.02m
  • Website:

Number of Employees


  • Leap Therapeutics, Inc.
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge
  • Massachusetts
  • 2141
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LPTXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 2017
5MC1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.